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ADMEAbstract Over expression of 11b-HSD 1 in key metabolic tissues is related to the development of
type 2 diabetes, obesity, hypertension and metabolic syndrome. Nephrotoxicity of corosolic acid
(selective inhibitor of 11b-HSD 1) is recently reported, which is one of the major drawback. There-
fore, it is of great interest to find out the selective 11b-HSD 1 inhibitors without nephrotoxicity.
Using crystal structures of 11b-HSD 1 in complex with inhibitors as a source of structural informa-
tion, a combined structure-based virtual screening approach followed by PASS toxicity prediction,
Lipinski’s rule and ADME prediction was implemented to find out the potent and selective 11
b-HSD 1 analog of corosolic acid without nephrotoxicity. Two compounds with NCBI compound
identification number CID59752459 (Genins of Asiatic acid) and CID 119034 (Asiatic acid) were
found to be selective for the 11b-HSD 1 enzyme without nephrotoxicity which comply witholic syn-
Fig. 1 Inte
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drome by virtual based screening. Arabian JLipinski’s rule and ADME parameter defined for human use. However, none of the hits inhibited
11b-HSD 2 at 100 lM indicating their selectivity against 11b-HSD 1.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prevalence of obesity and its metabolic complications has
been increasing rapidly over the past two decades. Obesity is
associated with an increased risk of type 2 diabetes, metabolic
syndrome, cardiovascular disease, stroke and certain cancers
(Zimmet et al., 2001). However, the medicine for treatment
of type 2 diabetes is far from sufficient. So the development
of novel agents with good therapeutic index and low side
effects is still in urgent demand (Skyler, 2004). Metabolic syn-
drome is a prediabetic state, which features with abdominal
obesity, impaired glucose tolerance, dyslipidemia, low-levels
of high density lipoprotein (HDL), and hypertension (Jarrett
et al., 1996). When metabolic syndrome progresses to diabetes,
complications associating with this disorder, including cardio-
vascular disease, kidney failure and diabetic retinopathy,
become prominent. Recent investigations revealed that aber-
rant glucocorticoid receptor (GR) signaling was closely associ-
ated with metabolic syndrome. Glucocorticoid hormones,
including cortisone and cortisol in human, are important reg-
ulators of glucose and lipid homeostasis (Tomlinson et al.,
2004). Elevated level of glucocorticoids can lead to insulin
resistance by decreasing insulin-dependent glucose uptake,
enhancing hepatic gluconeogenesis, and inhibiting insulin
secretion from pancreatic cells. Patients with sustained gluco-
corticoid excess will develop dyslipidemia, visceral obesity,
and other metabolic syndromes (Arnaldi et al., 2003). 11b-
hydroxysteroid dehydrogenase (11b-HSD) catalyzes the inter-
conversion of the glucocorticoids, cortisone and cortisol, in
human (Fig. 1) (Stewart et al., 1993). 11b-HSD has two iso-
form, 11b-HSD 1 and 11b-HSD 2. 11b-HSD 1, which is pri-
marily found in liver, adipose and brain, converted the
inactive cortisone to the active cortisol. Its counterpart 11b-
HSD 2, which is mainly expressed in kidney, catalyzes the
reverse conversion. Both 11b-HSD 1 and 11b-HSD 2 are
involved in maintenance of the balance of glucocorticoid hor-
mones as shown in Fig. 1. Evidence from the homozygous 11
b-HSD 1 knock-out mice model revealed that impaired func-
tion of 11b-HSD 1 could result in reducing of gluconeogenesisrconversion of cortisone and cor
al., In search of selective 11b-HSD type
ournal of Chemistry (2015), http://dx.dand lipophilia in liver, and increasing of insulin sensitivity.
However, inhibition of 11b-HSD 2 would lead to sodium
retention, hypokalemia and hypertension (Walker et al.,
1995; Kotelevtsev et al., 1999). Therefore, selective inhibition
of 11b-HSD 1 will be a therapeutic strategy to combat type
2 diabetes and obesity (Masuzaki et al., 2001; Davani et al.,
2004; Stulnig and Waldhaeusl, 2004; Deng et al., 2013).
Based on this view 11b-HSD 1 will be the better target for
treating the metabolic disorder and hence the multinational
pharmaceutical companies, such as Merck, Pfizer, Amgen,
and Abott are extensively working in discovering the 11b-
HSD 1 inhibitors for treating the diabetes (Fig. 2). Among
the 11b-HSD 1 inhibitors, carbenoxolone (CBO) is one of
the most commonly used, which is a semisynthetic derivative
of 18 b-glycyrrethinic acid a type of triterpene found in several
plants (Classen-Houben et al., 2009). However, the 11b-HSD 2
inhibitory activity of carbenoxolone was a limiting factor
because it induces renal mineralocorticoid excess at higher
doses (Walker et al., 1995). Other triterpenic acids, particularly
those with ursane or oleanane skeleton, are good inhibitors of
this enzyme but also inhibit the 11b-HSD 2 isoform, the one
that performs reverse reaction (Blum et al., 2009). Nephrotox-
icity of corosolic acid is recently reported, which is one of the
major drawbacks of this selective 11b-HSD 1 inhibitor. There-
fore, it is of great interest to find out the selective 11b-HSD 1
inhibitors without nephrotoxicity (Zheng et al., 2010).
The in silico evaluations, including virtual screening of
compound libraries are extensively studied for synthetic
compounds but the application of these tools to natural
product libraries or particular class of phytoconstituents is
underestimated (Goel et al., 2011). A number of potent and
selective 11b-HSD 1 inhibitors was reported up to now, some
of which are progressing to clinical trial (Fig. 2) (Ge et al.,
2010; Xiang et al., 2007). So unearthing the selective 11b-
HSD 1 inhibitors from the inexhaustible natural product
reservoir will be a promising project and hence current
research work deals with virtual screening of corosolic acid
analogs in order to get more selective and potent 11b-HSD 1
inhibitor without nephrotoxicity.tisol by 11b-HSD type 1 and 2 enzymes.
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Fig. 2 Representative 11b-HSD 1 inhibitors.
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In the present study, we have tried to find out the potent and
more 11b-HSD 1 selective analog of corosolic acid without
nephrotoxicity by structure based virtual screening approach.
The workflow of the virtual screening campaign is outlined
in Fig. 3. Very first structurally similar analogs of corosolic
acid were collected from NCBI database by performing simi-
larity search since corosolic acid is the structural analog of car-
benoxolone (non-selective) having selective 11b-HSD 1
inhibitory activity. Docking study of Corosolic acid analogs
was performed by Maestro 8.0 to find out affinity against 11
b-HSD1 enzyme. Those compounds showing highest docking
score were further subjected to the toxicity prediction by
PASS. Further we analyzed all the compounds for Lipinski’s
rule of five to evaluate drug likeness and established in silico
ADME parameters using QikProp to find out the selective
11 b-HSD1 inhibitors. In vitro enzyme inhibitory assay further
confirms our hypothesis.
2.1. Computer hardware and software
Structure based virtual screening is performed on Apple work-
station (8-core processor) using Glide and QuickPro module of
Schrodinger, LLC, New York, USA, 2008, on the windows XP
operating system. The crystal structure of 11b-HSD1 is
retrieved from the Protein Data Bank (PDB) with the acces-
sion code 2BEL (http://www.rcsb.org/pdb/explore/explore.
do?StructureId=2BEL). Toxicity prediction was carried out
by PASS version (Version 9.1, http://www.ibmc.msk.ru/
PASS). This software estimates the predicted toxicity spectrum
of a compound as probable activity (Pa) and probable inactiv-
ity (Pi). Prediction of this spectrum by PASS is based on SAR
analysis of the training set containing more than 205,000 com-
pounds exhibiting more than 3750 kinds of biological activities
(Poroikov et al., 2009).Please cite this article in press as: Patel, H. et al., In search of selective 11b-HSD type
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3234 similar analogs of corosolic acid were collected from
NCBI database (http://pubchem.ncbi.nlm.nih.gov/search/
search.cgi) by performing similarity search option in the NCBI
database. These compounds (3234 corosolic acid analogs) were
converted into Mol file by using ChemBiodraw Ultra 11.0.
Three-dimensional (3D) conversion and minimization were
performed using LigPrep (MMFFs force field) (Halgren
et al., 2004). Conformers were generated using a rapid torsion
angle search approach followed by minimization of each gen-
erated structure using the MMFFs force field, with an implicit
GB/SA solvent model using LigPrep 2.2. A maximum of 1000
conformers was generated per structure using a pre-process
minimization of 1000 steps and post-process minimization of
500 steps. Each minimized conformer was filtered through a
relative energy window of 50 kJ mol1 and a minimum atom
deviation of 1.00 A˚ (Evans et al., 2007). This value
(50 kJ mol1) sets an energy threshold relative to the lowest-
energy conformer. Conformers that are higher in energy than
this threshold are discarded. All distances between pairs of cor-
responding heavy atoms must be below 1.00 A˚ for two con-
formers to be considered identical. This threshold is applied
only after the energy difference threshold, and only if the
two conformers are within 1 kcal mol1 of each other.
2.3. Docking study
The molecular docking tool, GLIDE (Schordinger, USA) was
used for ligand docking studies into the 11b-HSD 1 enzyme
binding pocket. The crystal structure of 11b-HSD 1 was
obtained from the protein data bank (PDB: 2BEL). The protein
preparation was carried out using ‘protein preparation wizard’
in Maestro 8.0 in two steps, preparation and refinement. After
ensuring chemical correctness, hydrogens were added, where
they were missing. Using the OPLS 2005 force field energy of1 inhibitors without nephrotoxicity: An approach to resolve the metabolic syn-
oi.org/10.1016/j.arabjc.2015.08.003
Fig. 3 Virtual screening protocol.
4 H. Patel et al.crystal structure was minimized (Zhong et al., 2009). Grid was
defined centering them on the ligand in the crystal structure
using the default box size. The ligands were built using maestro
build panel and prepared by LigPrep 2.2 module, which pro-
duce the low-energy conformer of ligands using OPLS 2005Please cite this article in press as: Patel, H. et al., In search of selective 11b-HSD type
drome by virtual based screening. Arabian Journal of Chemistry (2015), http://dx.dforce field. The low-energy conformation of the ligands was
selected and was docked into the grid generated from protein
structures using standard precision (SP) docking mode. The
final evaluation is done with glide score (docking score) and sin-
gle best pose is generated as the output for a particular ligand.1 inhibitors without nephrotoxicity: An approach to resolve the metabolic syn-
oi.org/10.1016/j.arabjc.2015.08.003
An approach to resolve the metabolic syndrome by virtual based screening 52.4. PASS toxicity prediction
Toxicity of chemical compound is a complex phenomenon that
may be caused by its interaction with different targets in the
organism. Two distinct types of toxicity can be broadly speci-
fied: The first one is caused by the strong compound’s interac-
tion with a single target (e.g. AChE inhibition), while the
second one is caused by the moderate compound’s interaction
with many various targets. Computer program PASS predicts
about 2500 kinds of biological activities based on the struc-
tural formula of chemical compounds. Prediction is based on
the robust analysis of structure–activity relationships for about
60,000 biologically active compounds. Mean accuracy exceeds
90% in leave-one-out cross-validation. In addition to some
kinds of adverse effects and specific toxicity (e.g. carcinogenic-
ity, mutagenicity), PASS predicts approximately 2000 kinds of
biological activities at the molecular level, providing an esti-
mated profile of compound’s action in biological space. Such
profiles can be used to recognize the most probable targets,
interaction with which might be a reason of compound’s tox-
icity. Applications of PASS predictions for analysis of proba-
ble targets and mechanisms of toxicity are discussed (Poroikov
et al., 2007).
2.5. Drug likeness (Lipinski’s Rule of Five) and in silico ADME
study
Pharmacokinetic property optimization is a rather complex
undertaking that is likely to require changes in those molecular
determinants that are responsible for binding affinity and
specificity like hydrogen bonds. It is well known that numerous
drug candidates have failed during clinical tests because of
problems related to absorption, distribution, metabolism and
excretion (ADME) properties. We analyzed Lipinski’s rule
and in silico ADME properties using QikProp 2.3 module of
the Maestro 8.0. QikProp is a quick, accurate, easy-to-use
absorption, distribution, metabolism, and excretion (ADME)
prediction program designed by Professor William L. Jor-
gensen. QikProp predicts physically significant descriptors
and pharmaceutically relevant properties of organic molecules,
either individually or in batches (Lipinski et al., 2001; Vistoli
et al., 2008; Ertl et al., 2000).
2.6. Determination of half maximum inhibitory concentrations
(IC50)
2.6.1. 11b-HSD1 assay in rat microsomes
Six male adult rat testes were used for preparation of rat testis
microsomes to measure 11b-HSD1 activity, as they contained
a large amount of 11b-HSD1 enzyme (Ge and Hardy, 2000).
The preparation of microsomes was performed as described
previously (Guo et al., 2012). In brief, rat testes were homog-
enized in 0.01 mM PBS buffer containing 0.25 M sucrose. The
nuclei and large cell debris were removed by centrifugation at
1500g for 10 min. The post-nuclear supernatants were cen-
trifuged twice at 105,000g. The resultant microsomal pellets
were resuspended. Protein contents were measured by Nano-
Drop 2000 (Thermo Scientific). The microsomes (20 mg/mL)
were used for measurement of 11b-HSD1 or 11b-HSD2 activ-
ities. The rat testes microsomes (10 mg) were incubated with
substrate, 0.2 mM NADPH and 0.5 mM glucose-6-phosphatePlease cite this article in press as: Patel, H. et al., In search of selective 11b-HSD type
drome by virtual based screening. Arabian Journal of Chemistry (2015), http://dx.d(G6P) and various concentrations of the hit compounds 37 
C for 60–90 min. The inhibitory potency of hits was measured
relative to control (only DMSO). The hit compounds were dis-
solved in DMSO with final DMSO concentration of 0.4%, at
which DMSO did not inhibit this enzyme activity. The reaction
was stopped by adding 1 mL of ice-cold ether. The steroids
were extracted, and the organic layer was dried with N2. The
steroids were separated chromatographically on the thin layer
plate in chloroform and methanol (90:10,v/v), and the radioac-
tivity was measured using a scanning radiometer (System
AR2000, Bioscan Inc., Washington, DC) as described previ-
ously (Ge et al., 1997). The percentage conversion of 11DHC
to CORT, or cortisone to cortisol was calculated by dividing
the radioactive counts identified as 11-OH-steroids by the total
counts.
2.6.2. 11b-HSD2 assay in rat microsomes
Six male adult rat kidneys were used for preparation of rat kid-
ney microsomes to measure 11b-HSD2 as high levels of
11bHSD2 expression and activity (Klusonova et al., 2008).
Preparation of kidney microsomes was carried out as previ-
ously described (Guo et al., 2012). 11b-HSD2 activity assay
tubes contained 25 nM (within the range of physiological levels
of CORT). [3H] cortisol and [3H] CORT were used as sub-
strates to measure rat 11b-HSD2 oxidase activity. Kidney
microsomes were incubated with substrates, NADP. The reac-
tions were stopped by adding 1 mL of ice-cold ether. The ster-
oids were extracted, and the organic layer was dried with
nitrogen. The steroids were separated chromatographically
on thin layer plates in chloroform and methanol (90:10), and
the radioactivity was measured using a scanning radiometer
(System AR2000, Bioscan Inc., Washington, DC). The per-
centage conversion of CORT to 11DHC and cortisol to corti-
sone was calculated by dividing the radioactive counts
identified as 11DHC (or cortisone) by the total counts associ-
ated with both substrate and product.
3. Results and discussion
The virtual screening protocol used in this study is based on
the application of sequential filters to find out a selective
11b-HSD 1 inhibitor. The virtual screening campaign con-
ducted to screen novel 11b-HSD 1 inhibitors started with
search of 3234 similar analogs of corosolic acid from NCBI
database (http://pubchem.ncbi.nlm.nih.gov/search/search.cgi)
by performing similarity search option in the NCBI database
since corosolic acid is structural analog of carbenoxolone
(non-selective) having selective 11b-HSD 1 inhibitory activity.
Virtual screening of the compound libraries was carried out
with Schrodinger’s ligand docking tool in a two-step process,
consisting of first high-throughput virtual screening (HTVS)
and later standard precision (SP) docking. The molecular
docking tool, GLIDE (Schordinger Inc., USA) was used for
ligand docking studies into the 11b-HSD1 enzyme binding
pocket. The crystal structure of 11b-HSD1 was obtained from
the protein data bank (PDB: 2BEL). After HTVS, a Glide
score cutoff of -8.0 was used, and compounds with values
greater were discarded, leaving a total of 1562 ligands. Addi-
tionally, for the compound to be included for SP docking, at
least two of three hydrogen bonds must be present, one to
Tyr 183 and one of two possible to Ser 170. This resulted in1 inhibitors without nephrotoxicity: An approach to resolve the metabolic syn-
oi.org/10.1016/j.arabjc.2015.08.003
Table 1 Glide docking results (SP docking method) and toxicity prediction by PASS of selected hits.
NCBI 
Compound 
Identification 
Number (CID)
Structures
Hydrogen
Bond
Interaction
RMSD Glide 
Score
Glide 
evdw
Glide 
Energy
Glide 
emodel
H
Bond
TOXICITY
Pa Pi Toxicity
Corosolic acid
CID6918774
Selective 
Inhibitor
TYR-183 0.002 -7.74 -39.074 -40.39 -19.71 1 0,680 0,032 Nephrotoxic
Carbenoxolone
CID21913
Non-Selective 
Inhibitor
ILE-46,
GLY-47,
ASN-119
0.028 -7.805 -27.24 -35.43 -50.61 3 0,822 0,010 Nephrotoxic
CID21669127
GLY-216, 
TYR-183, 
SER-170
0.008597 -11.8467 -28.4839 -41.15 18.05165 3 - - -
CID11548915
ASN-119, 
ALA-42, 
GLY-47, 
SER-170
0.028694 -10.8643 -43.0415 -50.952 -38.5649 4 0,950 0,003 Nephrotoxic
NCBI 
Compound 
Identification 
Number (CID)
Structures
Hydrogen
Bond
Interaction
RMSD Glide 
Score
Glide 
evdw
Glide 
Energy
Glide 
emodel
H
Bond
TOXICITY
Pa Pi Toxicity
CID59752459
LYS-44, 
LYS-44, 
THR-222, 
SER-170
0.003929 -10.5962 -34.3363 -49.447 -53.5505 4 - - -
CID5319746
ASN-119, 
LYS-187, 
THR-183, 
SER-170
0.00738 -10.3903 -13.0297 -33.708 50.78204 4 - - -
CID12073158 TYR-183 0.046985 -10.315 -32.7476 -37.039 -21.9332 1 - - -
CID612532
TYR-183, 
GLY-216
0.002658 -10.2775 -22.6495 -31.748 13.70799 2 - - -
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NCBI 
Compound 
Identification 
Number 
(CID)
Structures
Hydrogen
Bond
Interaction
RMSD Glide 
Score
Glide 
evdw
Glide 
Energy
Glide 
emodel
H
Bond
TOXICITY
Pa Pi Toxicity
CID609112 TYR-183 0.003357 -10.2135 -32.3994 -37.250 -26.8141 1 0,804 0,013 Nephrotoxic
CID44470116 SER-170 0.0127 -10.2295 -35.8396 -42.061 -17.3579 2 - - -
CID57110617
TYR-177, 
SER-170, 
GLY-216
0.047592 -10.1085 -29.14 -40.182 13.78735 3 0,951 0,003 Nephrotoxic
CID11648525
GLY-216, 
SER-170, 
THR-220
0.008033 -9.9218 -28.7561 -41.051 6.160157 3 - - -
NCBI 
Compound 
Identification 
Number (CID)
Structures
Hydrogen
Bond
Interaction
RMSD Glide 
Score
Glide 
evdw
Glide 
Energy
Glide 
emodel
H
Bond
TOXICITY
Pa Pi Toxicity
CID5315633 TYR-183 0.000644 -9.77286 -33.6092 -40.105 -30.5426 1 - - -
CID70696198
GLY-47, 
GLY-41, 
ASN-119, 
SER-170, 
MET-233
0.002792 -9.64109 -41.8672 -52.753 -51.8224 5 0,922 0,004 Nephrotoxic
CID119034
TYR-183, 
SER-170
0.000955 -9.63596 -24.7625 -30.820 -25.6706 2 - - -
CID11605753 SER-170, SER-169 0.03209 -9.54355 -29.2385 -32.700 31.51918 2 0,758 0,019 Nephrotoxic
(continued on next page)
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NCBI 
Compound 
Identification 
Number (CID)
Structures
Hydrogen
Bond
Interaction
RMSD Glide 
Score
Glide 
evdw
Glide 
Energy
Glide 
emodel
H
Bond
TOXICITY
Pa Pi Toxicity
CID14432544 TYR-183 0.034414 -9.52721 -43.0948 -44.621 19.79395 1 0,765 0,018 Nephrotoxic
CID44272564 TYR-183 0.006191 -9.51601 -34.167 -39.117 -31.2415 1 - - -
RMSD: Root Mean Standard Deviation; Pa: Coefficient of Activation; Pi: Coefficient of Inhibition; (–) indicates no toxicity; Yellow Color:
Known inhibitor; Green Color Hits: Non-Nephrotoxic; Brick Red Color Hits: Nephrotoxic
8 H. Patel et al.544 compounds for SP docking of the previous total. After SP
docking, compounds with a docking score greater than 9.50
were automatically excluded, and a total of 16 compounds
were finalized by considering each of the compounds’ hydro-
gen bonding to the active site residues, particularly Tyr 183
and Ser 170 as shown in Table 1. Figs. 4 and 5 revealed that
all ligands binds to a common site located close to the nicoti-
namide ring in NADPH, forming hydrogen bond interaction
with Tyr 183 and Ser170 residues that have been reported as
essential for catalysis (Sun et al., 2008; Thomas and Potter,
2011). These 16 compounds were further passed through the
next filter of toxicity prediction by PASS (Version 9.1, http://
www.ibmc.msk.ru/PASS) (Table 1). This software estimates
the predicted toxicity spectrum of a compound as probableFig. 4 Binding mode of CID 21669127, CID 59752459, CID 531974
crystal structure of 11b-HSD 1 (PDB code: 2BEL).
Please cite this article in press as: Patel, H. et al., In search of selective 11b-HSD type
drome by virtual based screening. Arabian Journal of Chemistry (2015), http://dx.dactivity (Pa) and probable inactivity (Pi). Prediction of this
spectrum by PASS is based on SAR analysis of the training
set containing more than 205,000 compounds exhibiting more
than 3750 kinds of biological activities. Pass toxicity prediction
shows the nephrotoxicity of corosolic acid and carbenoxolone,
and hence we checked all the 16 ligands for nephrotoxicity,
and we got 10 hits devoid of this.
We employ the next filter of ‘‘Lipinski’s rule of five” for
further filtering of the hits obtained from the previous filter,
i.e. PASS toxicity filter (10 hits). As discussed by Lipinski,
molecular properties are closely related to the oral bioavail-
ability of a drug. Lipinski’s rule of five is a rule of thumb to
evaluate drug likeness, or determine whether a chemical com-
pound with a certain pharmacological or biological activity6 and CID 612532 with Tyr 183 and Ser 170 residues in the X-ray
1 inhibitors without nephrotoxicity: An approach to resolve the metabolic syn-
oi.org/10.1016/j.arabjc.2015.08.003
Fig. 5 Binding mode of CID 12073158, CID 44272564, CID 11648525 and CID 119034 with Tyr 183 and Ser 170 residues in the X-ray
crystal structure of 11b-HSD 1 (PDB code: 2BEL).
An approach to resolve the metabolic syndrome by virtual based screening 9has properties that would make it a likely orally active drug in
humans. The rule describes delicate balance among the molec-
ular properties of a compound that directly influence its phar-
macodynamics and pharmacokinetics and ultimately affect
their absorption, distribution, metabolism, and excretion in
the human body like a drug (Vistoli et al., 2008). In general,
these parameters allow to ascertain a poor oral absorption,
or membrane permeability, that occurs when the evaluated
molecules present values higher than five H-bond donors
(HBD), 10 H-bond acceptors (HBA), molecular weight
(MW) >500 Da and LogP (cLogP) >5 (Lipinski’s ‘rule-of-
five’) (Lipinski et al., 2001). The QikProp 3.2 was used to ana-
lyze drug likeness (Lipinski’s Rule of Five) and in silico ADME
evaluation; the results are given in Table 2 and it was found
that among the 10 hits only two comply with these rules
[CID59752459 (Genins of Asiatic acid) and CID 119034 (Asi-
atic acid)] and others are showing violation for Lipinski’s Rule
of Five.
However, it is important to note that there are many viola-
tions of this rule among existing drugs and vice versa, and
therefore, qualifying the ‘‘rule of five” does not guarantee that
a molecule is ‘‘drug-like” (Vistoli et al., 2008). Topological
polar surface area (TPSA) is now being recognized as a good
indicator of drug absorbance in the intestines, Caco-2 mono-
layer’s penetration, and blood brain barrier crossing (Ertl
et al., 2000). Topological polar surface area (TPSA), i.e., sur-
face belonging to polar atoms, is a descriptor that was shown
to correlate well with passive molecular transport through
membranes and, therefore, allows prediction of transport
properties of drugs in the intestines and blood brain barrier
crossing (Ertl et al., 2000). The percentage of absorption (%
ABS) was calculated using TPSA. Caco-2 cells are a model
for the gut-blood barrier. Caco-2 permeability is good indica-
tors of drug absorbance in the intestine. MDCK cells and logPlease cite this article in press as: Patel, H. et al., In search of selective 11b-HSD type
drome by virtual based screening. Arabian Journal of Chemistry (2015), http://dx.dBB are good markers to determine blood–brain barrier cross-
ing ability of compounds. Plog Khsa shows the prediction of
binding to human serum albumin. The result for ADME pre-
diction is shown in Table 2. Human Intestinal Absorption
(HIA) and Caco-2 (QPPCaco) permeability are good indica-
tors of drug absorbance in the intestine and Caco-2 monolayer
penetration, respectively. Human Intestinal Absorption data
are the sum of bioavailability and absorption evaluated from
the ratio of excretion or cumulative excretion in urine, bile
and feces (Zhao et al., 2001). The predicted percentage of
intestinal absorption is 76.997% and 85.169% for
CID59752459 (Genins of Asiatic acid) and CID 119034 (Asi-
atic acid) (obeys the Lipinski’s rule of five). The same com-
pounds present good permeability values in Caco-2
(QPPCaco) cells, i.e. 34.151–77.32 respectively and hence the-
oretically these two compounds should present good passive
oral absorption. The partition coefficient (QPlogPo/w) and
water solubility (QPlogS), critical for the estimation of absorp-
tion and distribution of drugs within the body for hit
CID59752459 (Genins of Asiatic acid) is 4 and 5.333 respec-
tively and for another hit with CID 119034 (Asiatic acid) it is 4
and 5.118. Cell permeability (QPPCaco), a key factor gov-
erning drug metabolism and its access to biological mem-
branes, is 34.151 and 77.32 for CID59752459 (Genins of
Asiatic acid) and CID 119034 (Asiatic acid) respectively. We
similarly studied the number of violations of Jorgensen’s rule
of three. The three rules are QPlogS > 5.7, QPCaco > 22,
Primary Metabolites <7. Compounds with fewer (and prefer-
ably no) violations of these rules are more likely to be orally
available. Hits with a compound identification number
CID59752459 (Genins of Asiatic acid) and CID 119034 (Asi-
atic acid) are following this rule, showing best candidate for
oral bioavailability. Similarly, CID 5319746 and CID
44470116 also follow Jorgensen’s rule but fail for the Lipnski’s1 inhibitors without nephrotoxicity: An approach to resolve the metabolic syn-
oi.org/10.1016/j.arabjc.2015.08.003
Table 2 Lipinski’s rule of five and ADME prediction of those Hits which are devoid of nephrotoxicity.
Criteria Lipinski’s Rule of Five (Drug Likeliness) In Silico ADME by QikProp, Schordinger 9.0
Sr.N
o.
Compounds Molecular Weight
QPlogP 
O/W a
H-bond
donor
H-bond
acceptor
Violation of
Lipinski’s Rule
QPlogSb QPlogHERGc QPPCaco d QPMDCK e QPlogKhsaf
% Human 
Oral 
Absorption g
Violation of 
Rule of Three
1 CID21669127 520.705 5 9.55 2.912 1 -4.654 -3.577 184.15 79.449 0.447 71.581 1
2 CID59752459 474.679 4 7.1 3.861 0 -5.333 -1.927 34.151 16.352 0.56 76.997 0
3 CID5319746 516.717 3 9.1 3.494 1 -5.393 -3.699 250.074 110.594 0.686 77.366 0
4 CID12073158 504.706 5 8.8 3.232 1 -5.049 -2.038 19.375 8.861 0.343 55.952 2
5 CID612532 502.733 2 6.1 5.208 2 -6.352 -3.573 966.756 476.957 1.273 84.953 1
6 CID44470116 504.706 5 8.8 3.209 1 -4.523 -1.539 34.97 16.776 0.288 60.403 0
7 CID11648525 472.707 2 4.4 5.691 1 -6.612 -1.675 118.579 62.792 1.263 84.428 1
8 CID5315633 504.706 4 9.5 2.759 1 -4.624 -3.68 144.899 61.314 0.396 68.819 1
9 CID119034 488.706 4 7.1 4.172 0 -5.118 -1.568 77.32 39.552 0.596 85.169 0
10 CID44272564 502.733 3 7.1 4.467 1 -6.404 -4.07 381.159 174.412 1.037 86.34 1
a Predicted octanol/water partition co-efficient log p (acceptable range: 2.0 to 6.5).
b Predicted aqueous solubility in mol/L (acceptable range: 6.5 to 0.5).
c Predicted IC50 value for blockage of HERG K+ channels (concern below 5.0).
d Predicted Caco-2 cell permeability in nM/s (acceptable range: <25 is poor and >500 is great).
e Predicted apparent MDCK cell permeability in nM/s.
f Prediction of binding to human serum albumin.
g Percentage of human oral absorption (<25% is poor and >80% is high).
Fig. 6 Structural comparison of Cortisol, Corosolic acid, Genins of Asiatic acid and Asiatic acid.
10 H. Patel et al.rule because of higher molecular weight exceeding 500. All
these pharmacokinetic parameters are within the acceptable
range for CID59752459 (Genins of Asiatic acid) and CID
119034 (Asiatic acid) defined for human use (see Table 2 foot-Please cite this article in press as: Patel, H. et al., In search of selective 11b-HSD type
drome by virtual based screening. Arabian Journal of Chemistry (2015), http://dx.dnote), thereby indicating their potential as a drug-like mole-
cule. The inhibitory effects on 11b-HSD1 of the hit
compounds CID59752459 (Genins of Asiatic acid) and CID
119034 (Asiatic acid) (shown in Table 3) were evaluated using1 inhibitors without nephrotoxicity: An approach to resolve the metabolic syn-
oi.org/10.1016/j.arabjc.2015.08.003
Table 3 Rat 11b-HSD1 and 11b-HSD2 inhibition of virtually screen hits.
NCBI Compound 
Identification Number (CID)
Structures Rat 11β-HSD 1
IC50 ( nM )
Rat 11β-HSD 2
IC50 ( nM ) Nephrotoxicity
CID 59752459
(Genins of Asiatic Acid) 240 >10,000
Nephroprotective 
(Xu et al., 2013).
CID119034
(Asiatic acid) 215 >10,000
Nephroprotective 
(Xu et al., 2013).
An approach to resolve the metabolic syndrome by virtual based screening 11the methods described previously (Guo et al., 2012). The IC50
was determined by adding 25 nM substrate, 0.2 mM co-factor
and various concentrations of hit compounds CID59752459
(Genins of Asiatic acid) and CID 119034 (Asiatic acid) in
250 mL reaction buffer (0.1 mM PBS) containing rat microso-
mal protein. Significant 11b-HSD1 enzyme inhibitory effects in
rats were exhibited by CID59752459 (Genins of Asiatic acid)
and CID 119034 (Asiatic acid), with IC50 values of 240 and
215 nM. However, none of the hits inhibited 11b-HSD2 at
100 lM indicating their selectivity against 11bHSD1.
Due to the structural similarities of both CID 59752459 and
CID119034 with the glucocorticoid receptor substrate, the
potential for cross-reactivity of these compounds with the glu-
cocorticoid receptor has been predicted using the PASS soft-
ware and in silico result shows no cross-reactivity with
glucocorticoid receptor.
However, small changes to the structures of the inhibitors
could generate compounds with high affinity for type 1 iso-
form, earlier reported by Rollinger et al., such as corosolic acid
which has an ursane structure and two hydroxyl groups on
positions 2 and 3 that result on determinant factors for its inhi-
bitory and specific activity (Rollinger et al., 2010). These com-
pounds are examples of the so-called selectivity cliffs, because
they show a closely related structural similarity but large
changes in biological activity (Medina-Franco, 2012). Struc-
tural comparison of corosolic acid and virtually screened hit
indicates that the presence of hydroxymethyl group at 4th
position favors the selectivity toward 11b-HSD 1 (see Fig. 6).
It is well reported that Asiatic acid is nephroprotective in
nature thus confirming our goal of the study (Xu et al.,
2013).
4. Conclusion
In summary, we performed a successful virtual based screening
on 3234 structurally similar analogs of corosolic acid collected
from NCBI database. Corosolic acid is the structural analog of
carbenoxolone (non-selective) having selective 11 b-HSD1
inhibitory activity with adverse effect of nephrotoxicity. There-
fore, it is of great interest to find out the selective 11b-HSD 1
inhibitors without nephrotoxicity. From 3234 structurallyPlease cite this article in press as: Patel, H. et al., In search of selective 11b-HSD type
drome by virtual based screening. Arabian Journal of Chemistry (2015), http://dx.dsimilar analogs of corosolic acid, two hits with NCBI com-
pound identification number CID59752459 (Genins of Asiatic
acid) and CID 119034 (Asiatic acid) were found to be selective
for the 11b-HSD1 enzyme without nephrotoxicity which com-
ply with Lipinski’s rule and ADME parameter defined for
human use. Significant 11b-HSD 1 enzyme inhibitory effects
were exhibited by CID59752459 (Genins of Asiatic acid) and
CID 119034 (Asiatic acid), with IC50 values 240 and 215 nM.
However, none of the hits inhibited 11b-HSD 2 at 100 lM
indicating their selectivity against 11b-HSD1. The identified
hits represent a very promising starting point for the develop-
ment of potent and selective 11b-HSD1 inhibitor with poten-
tial for treatment of important diseases such as type 2
diabetes, obesity, hypertension and metabolic syndrome with-
out nephrotoxicity.References
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